Use | Ampixicam is a new type of long-acting xixicam non-steroidal anti-inflammatory drug jointly developed by Pfizer Pharmaceuticals and Toyama Chemical Co., Ltd. of Japan. It is a prodrug of piroxicam and is hydrolyzed by enzymes after oral administration. It shows activity and is a cyclooxygenase inhibitor. This product has the remarkable characteristics of strong effect, long duration, high safety, good gastrointestinal tolerance, etc., and has attracted much attention in the pharmaceutical market. Animal experiments show that this product has the same analgesic and anti-inflammatory effects as piroxicam, and the inducing effect of gastric mucosal damage is far weaker than piroxicam. Clinically, this product 27mg has approximately the same bioavailability as piroxicam 20mg. |